Aerovate Therapeutics Stock (NASDAQ:AVTE)
Previous Close
$2.79
52W Range
$1.25 - $32.41
50D Avg
$2.05
200D Avg
$12.26
Market Cap
$78.52M
Avg Vol (3M)
$761.18K
Beta
1.03
Div Yield
-
AVTE Company Profile
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.